3 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 24 points (0.2%) at 14,421 as of Monday, March 11, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,375 issues advancing vs. 1,531 declining with 142 unchanged.

The Health Care sector currently sits up 0.4% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the sector include Aetna ( AET), down 1.7%, Shire ( SHPG), down 0.7%, Agilent Technologies ( A), down 0.7% and AstraZeneca ( AZN), down 0.5%. Top gainers within the sector include HCA Holdings ( HCA), up 2.0%, Cigna ( CI), up 1.2%, Novo Nordisk A/S ( NVO), up 1.2%, Express Scripts ( ESRX), up 1.0% and Intuitive Surgical ( ISRG), up 0.9%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector lower today:

3. Edwards Life ( EW) is one of the companies pushing the Health Care sector lower today. As of noon trading, Edwards Life is down $1.81 (-2.0%) to $88.49 on heavy volume Thus far, 857,578 shares of Edwards Life exchanged hands as compared to its average daily volume of 934,500 shares. The stock has ranged in price between $87.19-$89.46 after having opened the day at $89.46 as compared to the previous trading day's close of $90.30.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases or critically ill patients worldwide. Edwards Life has a market cap of $10.1 billion and is part of the health services industry. The company has a P/E ratio of 35.9, above the S&P 500 P/E ratio of 17.7. Shares are up 0.1% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Edwards Life a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Edwards Life Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $1.54 (-0.9%) to $171.43 on light volume Thus far, 134,642 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 819,200 shares. The stock has ranged in price between $171.29-$173.10 after having opened the day at $172.91 as compared to the previous trading day's close of $172.97.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $16.4 billion and is part of the drugs industry. The company has a P/E ratio of 25.5, above the S&P 500 P/E ratio of 17.7. Shares are up 0.5% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Amgen ( AMGN) is down $1.22 (-1.3%) to $91.78 on average volume Thus far, 2.1 million shares of Amgen exchanged hands as compared to its average daily volume of 5.5 million shares. The stock has ranged in price between $91.60-$93.36 after having opened the day at $92.66 as compared to the previous trading day's close of $93.00.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $69.6 billion and is part of the drugs industry. The company has a P/E ratio of 16.8, below the S&P 500 P/E ratio of 17.7. Shares are up 7.8% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Global Stocks Slide as Yield Pressure, Commodity Surge Prompts Equity Exit

Global Stocks Slide as Yield Pressure, Commodity Surge Prompts Equity Exit

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower